Micafungin Accord (Micafungin)

Micafungin blocks the enzyme β‑(1,3)‑D‑glucan synthase, preventing the synthesis of β‑(1,3)‑D‑glucan, an essential component of the fungal cell wall. This disruption weakens the wall, causing osmotic instability and leading to fungal cell death while sparing human cells.

The specific dose and duration of Micafungin Accord are determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and other clinical factors. The product is supplied as an injectable solution for intravenous administration.

The pregnancy safety category for micafungin is not definitively established. Use during pregnancy or lactation should only occur when the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician.

To place an order, submit an enquiry on the Micafungin Accord product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Micafungin belongs to the echinocandin class, which targets the fungal cell wall, unlike azoles that inhibit ergosterol synthesis. Echinocandins, including micafungin, are generally well‑tolerated and have fewer drug‑drug interactions, but they are administered intravenously, whereas many azoles are available orally.

Micafungin Accord should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution to maintain stability and potency.

Micafungin Accord is given as an intravenous infusion over a period typically ranging from 30 to 60 minutes, depending on the clinical protocol. Administration is performed by qualified healthcare professionals in a controlled setting such as a hospital infusion unit.

Serious risks include hepatic failure, severe allergic reactions such as anaphylaxis, infusion‑related hypotension or bronchospasm, and significant hematologic abnormalities like neutropenia or thrombocytopenia. Patients should be monitored closely for signs of liver dysfunction, allergic response, and blood count changes during therapy.

Micafungin Accord is contraindicated in patients with known hypersensitivity to micafungin or any component of the formulation. Caution is also advised for individuals with severe hepatic impairment, uncontrolled renal failure, or those receiving interacting medications that could increase toxicity.